Literature DB >> 34208938

Identification of Potential Biomarkers and Biological Pathways for Poor Clinical Outcome in Mucinous Colorectal Adenocarcinoma.

Chang Woo Kim1, Jae Myung Cha2, Min Seob Kwak2.   

Abstract

Colorectal cancer (CRC) comprises several histological subtypes, but the influences of the histological subtypes on prognosis remains unclear. We sought to evaluate the prognosis of mucinous adenocarcinoma (MAC), compared to that of traditional adenocarcinoma (TAC). This study used the data of patients diagnosed with CRC between 2004 and 2016, as obtained from the Surveillance, Epidemiology, and End Results database. We established a predictive model for disease-specific survival using conditional survival forest, model, non-linear Cox proportional hazards, and neural multi-task logistic regression model and identified the gene signatures for predicting poor prognosis based on the arrayexpress datasets. In total, 9096 (42.1%) patients with MAC and 12,490 (58.9%) patients with TAC were included. Those with the MAC subtype were more likely to have a poorer overall survival rate compared to those with the TAC subtype in stage II CRC (p = 0.002). The eight major genes including RPS18, RPL30, NME2, USP33, GAB2, RPS3A, RPS25, and CEP57 were found in the interacting network pathway. MAC was found to have a poorer prognosis compared to TAC, especially in Stage II CRC. In addition, our findings suggest that identifying potential biomarkers and biological pathways can be useful in CRC prognosis.

Entities:  

Keywords:  biomarker; colorectal cancer; gene; mucinous; survival

Year:  2021        PMID: 34208938     DOI: 10.3390/cancers13133280

Source DB:  PubMed          Journal:  Cancers (Basel)        ISSN: 2072-6694            Impact factor:   6.639


  2 in total

1.  Prognosis and Sensitivity of Adjuvant Chemotherapy in Mucinous Colorectal Adenocarcinoma without Distant Metastasis.

Authors:  Jun-Woo Bong; Jeong-An Gim; Yeonuk Ju; Chinock Cheong; Sun-Il Lee; Sang-Cheul Oh; Byung-Wook Min; Sanghee Kang
Journal:  Cancers (Basel)       Date:  2022-03-02       Impact factor: 6.639

2.  Redefining and expanding the sphere of influence of BRCA in breast and colorectal cancers and beyond.

Authors:  Emil Lou
Journal:  Oncotarget       Date:  2022-01-14
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.